The global bispecific antibodies market is anticipated to grow at a significant CAGR during the forecast period (2021-2027). The major factor attributed to the market growth includes the rising prevalence of cancer all over the globe. Presently, there are above 300 drug candidates available for the bispecific antibodies for cancer. Majority of these drug candidates are in their pre-clinical or clinical trial stages. Various medical technology providers and drug developers operating within the global bispecific antibodies for cancer market have entered into strategic collaborations together by signing numerous licensing agreements. These efforts are undertaken to advance the development of promising pipeline drug candidates with unique pharmacological and biological properties in the global bispecific antibodies market.

Cancer had proven to be one of the most chronic diseases globally which is further responsible for a large number of fatalities all over the globe. Therefore, as a measure to control this situation and avoid the further prevalence of cancer, the global bispecific antibodies market is likely to grow. Due to this, substantial growth in the number of clinical trials aimed towards the development of potent and advanced bispecific drugs during the past decade has acted favorably for the global bispecific antibodies market. These trials have made these drugs a popular as well as a promising candidate for enhanced treatment of various rare medical conditions, especially a variety of cancers. Presently, Blincyto, Hemlibra and Rybrevant are available in the commercial market, which are further likely to grow in the forecast period. 

Market Coverage

• The market number available for – 2020-2027

• Base year- 2020

• Forecast period- 2021-2027

• Segment Covered- 

o By Drug Type

o By Indication

o By Distribution Channel

• Regions covered-

o North America

o Europe

o Asia-Pacific

o Rest of the World

• Competitive Landscape:  Sanofi S.A., AbbVie Inc., and Pfizer Inc., among others.

Key questions addressed by the report

• What is the market growth rate?

• Which segment and region dominate the market in the base year?

• Which segment and region will project the fastest growth in the market?

• How COVID-19 impacted the market?

o Deviation from the pre-COVID-19 forecast

o Most affected region and segment

• Who is the leader in the market?

• How are players addressing challenges to sustain growth?

• Where is the investment opportunity?

Global Bispecific Antibodies Market Report by Segment

By Drug Type

• Blinatumomab

• Catumaxomab

• Duligotumab

By Indication

• Cancer

• Infectious Disease

• Inflammatory and Autoimmune Disorders

• CNS Disorders

By End-User

• Hospital Pharmacies

• Retail Pharmacies

• Drug Stores

• Online Pharmacies

Global Bispecific Antibodies Market Report by Region

North America       

• US

• Canada

Europe

• Germany

• UK

• France

• Spain

• Italy

• Rest of Europe

Asia-Pacific    

• China

• Japan

• India

• Rest of Asia-Pacific

Rest of the World

• Latin America

• Middle East and Africa